Pharmacists United for Truth and Transparency (PUTT) is set to host its 2025 PUTT Summit on Wednesday, September 24th, bringing together experts and legislators for an in-depth discussion on crucial pharmacy benefit manager (PBM) reform issues. The virtual event, scheduled from 10 am to 2 pm ET (9 am to 1 pm CT), aims to provide a platform for useful Q&A sessions and a deep dive into the complexities surrounding PBM practices. As stated in the organization's recent tweet, "DYK: The 2025 PUTT Summit is Only 2 Weeks Away! Don't miss your chance to take a deep dive into the issues & experience useful Q&A with experts and legislators!"
PUTT, a national non-profit watchdog group, advocates for transparency and accountability within the PBM industry. The organization asserts that PBMs, initially designed to manage prescription drug benefits and control costs, have evolved into powerful middlemen whose practices often lead to inflated drug prices, reduced patient choice, and financial strain on independent pharmacies. Their advocacy focuses on addressing issues such as "spread pricing," where PBMs profit from the difference between what they charge health plans and what they reimburse pharmacies.
The push for PBM reform has gained significant traction at both state and federal levels, driven by concerns over market consolidation and anti-competitive behaviors. Recent legislative efforts, such as Arkansas's House Bill 1150, have aimed to prohibit PBMs from operating their own pharmacies while simultaneously managing benefits, addressing a key conflict of interest. PUTT has been a vocal supporter of such measures, alongside broader calls for full drug acquisition cost reimbursement and patient choice of pharmacy.
The upcoming summit underscores the ongoing urgency for comprehensive PBM reform. Participants will have the opportunity to engage directly with stakeholders working to enact meaningful changes that protect patients and ensure the viability of local pharmacies. This gathering serves as a critical forum for advancing the dialogue and strategizing next steps in the collective effort to reform the prescription drug marketplace.